Category Archives: Global News Feed

See original here:
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at CHEST 2021, the annual meeting of the American College of CHEST Physicians, which will be held virtually October 17-20.

Follow this link:
Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021

LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Peter Piot has resigned as Chairperson of the Respiratory Diseases Scientific Advisory Board due to important responsibilities advising a major governmental organization on COVID-19 that creates a conflict.

Read the original post:
Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity

DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug Administration (FDA) notified the company that the review of the New Drug Application (NDA) for FT218 is still ongoing, and action will likely not be taken in October. The FDA informed the company that there are no information requests at this time and a new target action date will be provided as soon as possible.

Here is the original post:
Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy

– Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro –

Read the original here:
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion...

FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Zacks Small Cap Research has issued an update report on the company which may be accessed at:

Original post:
ABVC BioPharma Report Updated by Zacks/SCR

IRVINE, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it expects final patient enrollment in its endpoint clinical trial for its InFoods® diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. The clinical trial is being conducted by Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist hospital and the University of Michigan as primary enrollment centers for this study.

Read the original here:
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week

Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple Indications Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple Indications

Read the original post:
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director

NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.

See more here:
Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease diagnostics, announced today that the Company’s manufacturing partner Empowered Diagnostics has filed an amended emergency use authorization (EUA) with the Food and Drug Administration (FDA) for ImmunoPass™, the Company’s rapid test that detects COVID-19 neutralizing antibodies at point-of-care locations.

Here is the original post:
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19...